Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
08 February 2024 - 12:30AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO SECTION 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of February 2024
Commission
File Number: 001-39950
Evaxion
Biotech A/S
(Exact
Name of Registrant as Specified in Its Charter)
Dr. Neergaards
Vej 5f
DK-2970
Hoersholm
Denmark
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x Form 40-F
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
INCORPORATION
BY REFERENCE
This report
on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S’s registration statements
on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050)
and Form F-1 (File No. No. 333-276505), including any prospectuses forming a part of such registration statements and to be a part thereof
from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
Press
Release
On February
7, 2024, Evaxion Biotech A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™
powered vaccines, issued a press release announcing that the Company had regained compliance with the Nasdaq minimum bid price deficiency.
A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
Evaxion
Biotech A/S |
|
|
Date: February
7, 2024 |
By: |
/s/
Christian Kanstrup |
|
|
Christian Kanstrup |
|
|
Chief Executive Officer |
|
|
|
Exhibit 99.1
Evaxion Regains Compliance with Nasdaq Minimum
Bid Price Requirement
COPENHAGEN,
Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”),
a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on February 05,
2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2).
The Notification Letter confirmed that the closing
bid price of the Company’s American Depositary Shares has been at $1.00 per share or greater for ten consecutive business days from
January 22, 2024, to February 02, 2024, and that the Company has regained compliance with the listing rules of the Nasdaq Capital Market.
About EVAXION
Evaxion
Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable
AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies
for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology
pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet
medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For
more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit
our website.
Contact Information
Evaxion Biotech
A/S
Christian
Kanstrup
Chief Executive
Officer
cka@evaxion-biotech.com
Source: Evaxion Biotech
Forward-Looking
Statement
This announcement
contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,”
“hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,”
“continue,” “estimate,” “plan,” “potential,” “predict,” “project,”
“will,” “can have,” “likely,” “should,” “would,” “could,” and
other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial
condition and need for additional capital; our development work; cost and success of our product development activities and preclinical
and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate
and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing
and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights;
employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance,
social and business factors, including inflation, and the effects on our business from the worldwide ongoing COVID-19 pandemic and
the ongoing conflict in the region surrounding Ukraine and Russia and the Middle East; and other uncertainties affecting
our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included
in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC),
which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements
except as required by law.
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From May 2023 to May 2024